betes mellitus has been reported in Finland and Sweden [3] . As both MODY and MIDD mostly present with a young onset and insulin deficient phenotype, it is probable that patients with these monogenic types of diabetes are frequently misclassified as having Type I diabetes. The contribution of these monogenic forms of diabetes to the high prevalence of early-onset diabetes in Finland and Sweden is not known. The aim of our study was to establish the prevalence of MODY and mitochondrial mutations in 115 patients diagnosed with diabetes at 40 years of age or younger and with a strong family history of diabetes.
Materials and methods
Subjects and measurements. In total 115 families with early-onset diabetes were selected from 1350 Swedish and Finnish families. Of them, there were 3 families with 1 patient, 41 families with 2 patients, 71 families with 3 or more patients diagnosed with diabetes at 40 years of age or younger [4] . On average, the pedigrees included 9 subjects with four diabetic patients per family. From each family, one patient with early-onset ( £ 40 years) diabetes was chosen for mutation screening. Of the 115 selected probands, 80 % had a first-degree relative diagnosed with diabetes at 40 years of age or younger. There were 48 probands who had originally been diagnosed with Type I diabetes by their physicians. Of them, 29 % (11/38) were positive for glutamic acid decarboxylase antibodies (GAD-Ab). About 66 % (23/35) of these patients had no measurable fasting serum C peptides ( > 0.03 nmol/l). Of the 115 families 12 fulfilled also the classical MODY criteria: autosomal dominant inheritance of diabetes in three generations and two diabetic patients with age at onset of 25 years or younger. In total 20 families fulfilled less stringent MODY criteria (diabetes in three generations and at least one diabetic patient with age at onset £ 25 years). The allele frequency of new sequence variants in the cohort was tested in 92 non-diabetic control subjects. In addition, the allele frequency of the HNF-1a gene variation A98V was tested in 118 unrelated Finnish Type II diabetic patients diagnosed with diabetes after the age of 40 years. Basic clinical characteristics of study subjects are presented in Table 1 . Studies were approved by the local ethics committees. Concentrations of glucose, insulin, C-peptide, HbA 1c , lipids and GAD-Ab were determined as described before [5] .
Mutation screening of MODY genes. Mutation screening of the HNF-4a, GCK and HNF-1a genes were done with the single strand conformation polymorphism (SSCP) technique and by direct sequencing. Primer sequences are presented in Table 2 . The sequencing was performed with a Thermo Sequenase dye terminator cycle sequencing pre-mix kit (Amersham Life Science, Cleveland, Ohio, USA) according to manufacturers' instructions using ABI373 A DNA Sequencer (Applied Biosystems, Foster City, Calif., USA). Each specific fragment was sequenced with the original primers in both directions and analysed using Sequencer software package (Gene Codes Corporation, Ann Arbor, Mich., USA).
Detection of the A3243G mutation in the mitochondrial tR-NA Leu gene. Total DNA was isolated from peripheral blood lymphocytes and amplified by using primers specific to mtDNA [2] . A 427 bp fragment, labelled with [a-32 P]dCTP during PCR cycling, was digested with Apa I at 37 C for 8 h. Samples were electrophoresed with constant power (50 W) on Values are presented as means ± SD. FB, fasting blood; FS, fasting serum; WHR, waist-to-hip ratio 5 % acrylamide gel under denaturing conditions for 3.5 h. Gels were then dried and exposed to films at ±70 C for 1±3 days.
Statistics. Data are expressed as means SD. The significance of frequency differences between groups was tested by Yates corrected chi-square test (BMDP Statistical Software, Los Angeles, Calif., USA). A p value less than 0.05 was considered statistically significant.
Results
The mutation screening of HNF-4a, GCK and HNF1a genes in the 115 unrelated early-onset diabetic patients resulted in 52 sequence variations, 12 of which were considered as MODY mutations. We found two HNF-4a (MODY1) mutations, a deletion of two adenines at codon 99 (K99fsdelAA) in exon 3 and an insertion of a valine between codons L328-L329 (V328±329ins) in exon 8. The clinical characterization of the DS-family, carrying the K99fsdelAA mutation, has been recently described [6] . We identified four novel mutations in the GCK (MODY2) gene: an amino acid substitution (G72R) in exon 3, two splice site variants (IVS3 + 1G > A and IV-S3±2A > G) on both sides of intron 3 and one in frame duplication of eight amino acids (133dupY125-D132) in exon 4. We found six mutations in the HNF-1a (MODY3) gene. Other than three previously reported variations (R131Q, R272 C, and Pro291fsinsC) [7, 8] , we identified one amino acid substitution (L107I in exon 1), one insertion (S315fsinsA in exon 4) and one deletion (G375fsdelG in exon 6). In the LS-family, two diabetic R131Q mutation carriers (LS-3 and LS-8) also have a hereditary form of neuropathy, Charcot-Marie Tooth disease type 1 A (CMT1 A) (Fig. 1 ). An additional three families were found to carry a specific mutation (A3243G) in the mitochondrial tRNA Description of another 40 sequence variations in the HNF-1a, HNF-4a and glucokinase genes are presented in Table 3 . Of note, the Val98 allele in the HNF±1a gene, was three times more prevalent in the diabetic (n = 115) than in the control (n = 92) group (8.7 % vs 2.7 %; p = 0.02). When the subjects were divided according to the country of origin, the frequency of Val98 allele was six times more prevalent among Finnish (n = 68) than among Swedish (n = 47) diabetic patients (13.2 % vs 2.1 %; p = 0.007). The frequency of the Val98 allele was increased compared with 58 Finnish non±diabetic control subjects (13.2 % vs 3.5 %; p = 0.01). We also tested the frequency of the Val98 allele in 118 unrelated Finnish Type II diabetic patients, who had been diagnosed with diabetes after the age of 40 years. The Val98 allele was more common among early-onset ( £ 40 year) than among late-onset ( > 40 year) diabetic patients (13.2 % vs 4.2 %; p = 0.003).
Clinical characteristics of diabetic patients in MODY1±3, MODY(X) and MIDD families. We found MODY1±3 mutations in 7 out of 12 families fulfilling the classical MODY criteria (see methods). Since the remaining 5 families did not show any mutations in either the IPF1 (MODY4) or the HNF-1b (MODY5) genes (Weng and Lehto, unpublished observations), they were considered as MODY(X) families. Notably, 46 % (12 / 26) of diabetic patients in the MODY(X) families had originally been diagnosed with Type I diabetes and 42 % (11 / 26) had onset at 25 years of age or younger. Among the diabetic mutation carriers tested in MODY1±3 and MIDD families, the proportion of those 25 years of age or younger at onset was 100 % in MODY1 (7/7), 68 % in MODY3 (19/28), 60 % in MODY2 (6/10) and 27 % in MIDD (3/11). The clinical characteristics of diabetic patients in MODY1, MODY2, MODY3 (families HS, LS, IS), MIDD and MODY(X) families are summarised in Table 4 .
Discussion
It has been considered that about 10±15 % of patients with onset of diabetes before the age of 40 years has Type II diabetes and another 10 % is unclassifiable diabetes; mutation carrier; not tested [9] . Our study showed that 13 % of patients in this age group had mutations in MODY or mitochondrial genes. These patients were further characterized by a strong family history of diabetes. In addition, 40 other sequence variations in the HNF-1a, HNF-4a and glucokinase genes were identified in these patients, but it needs to be shown whether they result in functional defects. The HNF-1a amino acid substitution A98V has been associated with impaired insulin and C-peptide responses to glucose in Danish middle-aged control subjects [10] . Among Finnish subjects with early±on-set diabetes, the prevalence of the Val98 allele was about 13 %, which was statistically significantly higher than in non±diabetic control subjects (3.5 %) or in patients with late-onset Type II diabetes (4.2 %). In the Danish cohort, the prevalence of the Val98 allele was 3.7 % in late-onset Type II diabetes and 4.4 % in control subjects [10] .
Among the 12 classically defined MODY-families, 7 were found to carry a MODY-mutation. Since the remaining 5 families did not show mutations in the IPF1 (MODY4) or HNF-1b (MODY5) genes (Weng and Lehto, unpublished observations), they were considered as MODY(X) families. Low fasting Cpeptide concentrations and insulin requirement point in the MODY(X) patients at a severe pancreatic beta±cell dysfunction. Noteworthy, about half of the patients in the MODY(X) families had originally been given a diagnosis of Type I diabetes. Whether diabetes in these MODY(X) families is monogenic or polygenic in origin remains to be determined. In the MODY1±3 families, diabetic mutation carriers exhibited typical features of MODY, e. g. earlyonset, normal weight, low fasting C-peptide concentrations and a normal lipid profile. Although patients in the MIDD families had a similar BMI as the MODY patients, they tended to have a later onset, higher fasting C-peptide concentrations and diabetic dyslipidaemia. Therefore, the phenotype of the MIDD patients resembled more the phenotype of the insulin resistant Type II diabetic patients. Among the MODY patients, GAD-antibodies were detected in only 1 of 21 (4.8 %) subjects, which is similar to the frequency we have reported in Scandinavian non±diabetic subjects (4.4 %) [11] . Thus, GAD-antibodies do not seem to be a characteristic of MODY patients.
The families in the present study were selected based upon early-onset and family history of diabetes. Of 12 families 5 with a MODY-mutation did not meet the classical MODY-criteria. Of 15 probands with a defined genetic defect 2 had been given a diagnosis of Type I diabetes. Recent studies have shown that about 5±10 % of patients diagnosed with Type I diabetes could carry a mutation in the HNF-1a gene [12, 13] . In summary, among 115 families with early±onset ( £ 40 years) diabetes, mutations in the HNF-1a gene represented the most common cause of diabetes: MODY3 (5.2 %) more than MODY2 (3.5 %) more than MIDD (2.6 %) more than MODY1 (1.7 %). When these data were pooled with our previous findings ( [5, 6, 14] and unpublished observations), the following distribution of MODY was seen in 26 Scandinavian families: MODY1 (8 %), MODY2 (15 %), MODY3 (58 %) and MODY(X) (19 %). Of note, about 60 % of the Scandinavian MODY3 families carried a ªhotspotº mutation Pro291fsinsC [14] . A similar frequency of different MODY forms has recently been reported in a British cohort [1] . Recent studies of MODY families have shown that mutations in the IPF1 and HNF-1b genes are very rare [15±17], which suggest that other still unknown MODY genes could be identified in the future.
